COCP - CIK 0001412486
Cocrystal Pharma, Inc. trades as COCP. In its fiscal 2020 annual report the company posted revenue of $2.01M, down 69.3% from the prior year and net income of -$8.83M. This page tracks Cocrystal Pharma, Inc. through 655 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Proxy materials | DEFA14A | 2026-05-27 |
| Proxy statement | DEF 14A | 2026-05-27 |
| Major company event | 8-K | 2026-05-26 |
| Quarterly report | 10-Q | 2026-05-15 |
| EFFECT | - | 2026-05-01 |
| Major company event | 8-K | 2026-04-30 |
| Securities registration | S-3 | 2026-04-23 |
| Major company event | 8-K | 2026-04-02 |
The largest companies sharing Cocrystal Pharma, Inc.'s SEC industry classification (pharmaceutical preparations).
Cocrystal Pharma, Inc. reported revenue of $2.01M for fiscal year 2020, a decrease of 69.3% year over year.
In its latest fiscal year Cocrystal Pharma, Inc. reported a net loss of $8.83M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.